Recent Advances in the Search for the -Opioidergic System

The newly discovered endogenous μ-opioid receptor (MOP-R) ligands endomorphin-1 (EM-1) and -2 (EM-2) exhibit the highest specificity and affinity for the MOP-R of any endogenous substance so far described in the mammalian nervous system. This review focuses on differential mechanism of the motivational effects induced by EM-1 and EM-2. In the [35S]GTPγS binding assay, either EM-1 or EM-2 causes a concentration-dependent G-protein activation in brain membrane of normal mice, whereas neither EM-1 nor EM-2 produces any activation of G-protein in membranes obtained from the MOP-R knockout mice. These results provide direct evidence at the molecular level that both EMs act on the MOP-R as the endogenous MOP-R agonists. Based on the conditioned place preference paradigm in mice, EM-1 given intracerebroventriculally produced a dose-related place preference. This effect was abolished by pretreatment with the MOP-R antagonist β-funaltrexamine (FNA) but not the δ-opioid receptor (DOP-R) antagonist naltrindole and the κ-opioid receptor (KOP-R) antagonist nor-bialtorphimine (BNI). Unlike EM-1, EM-2 exhibited a place aversion. The aversive effect was inhibited by not only β-FNA but also nor-BNI. Place aversion produced by EM-2 was also attenuated by pretreatment with an antiserum against an endogenous KOP-R ligand dynorphin A(1 – 17). These findings indicate that EM-1 may produce its rewarding effect via MOP-Rs. Furthermore, the aversive effect induced by EM-2 may be associated with the stimulation of the EM-1-insensitive MOP-R subtype and necessarily activate an endogenous KOPergic system in the mouse brain.

[1]  I. Sora,et al.  Antagonistic property of buprenorphine for putative ϵ-opioid receptor-mediated G-protein activation by β-endorphin in pons/medulla of the μ-opioid receptor knockout mouse , 2002, Neuroscience.

[2]  L. Tseng The antinociceptive properties of endomorphin-1 and endomorphin-2 in the mouse. , 2002, Japanese journal of pharmacology.

[3]  K. Murayama,et al.  Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse. , 2001, European journal of pharmacology.

[4]  M. Narita,et al.  Partial agonistic action of endomorphins in the mouse spinal cord , 2001, Neuroscience Letters.

[5]  J. Kampine,et al.  Differential antinociception induced by spinally administered endomorphin-1 and endomorphin-2 in the mouse. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  M. Narita,et al.  Lack of the involvement of μ1-opioid receptor subtype on motivational effects induced by the endogenous μ-opioid receptor ligands endomorphin-1 and -2 in the mouse , 2001, Neuroscience Letters.

[7]  M. Narita,et al.  Different motivational effects induced by the endogenous μ-opioid receptor ligands endomorphin-1 and -2 in the mouse , 2001, Neuroscience.

[8]  G. Pasternak Insights into mu opioid pharmacology the role of mu opioid receptor subtypes. , 2001, Life sciences.

[9]  G. Pasternak Incomplete cross tolerance and multiple mu opioid peptide receptors. , 2001, Trends in pharmacological sciences.

[10]  M. Narita,et al.  Activation of G-proteins in the mouse pons/medulla by β-endorphin is mediated by the stimulation of μ- and putative ε-receptors , 2000 .

[11]  K. Murayama,et al.  Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone , 2000, Brain Research.

[12]  M. Narita,et al.  Differential involvement of μ1-opioid receptors in endomorphin- and β-endorphin-induced G-protein activation in the mouse pons/medulla , 2000, Neuroscience.

[13]  M. Ohsawa,et al.  Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse. , 2000, The Journal of pharmacology and experimental therapeutics.

[14]  N. Dun,et al.  G protein activation by endomorphins in the mouse periaqueductal gray matter. , 2000, Journal of biomedical science.

[15]  J. Kampine,et al.  Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. , 2000, The Journal of pharmacology and experimental therapeutics.

[16]  G. Pasternak,et al.  Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR‐1F , 2000, FEBS letters.

[17]  M. Szikszay,et al.  Antinociceptive effects of intrathecal endomorphin-1 and -2 in rats. , 1999, Life Science.

[18]  G. Pasternak,et al.  Antagonism of heroin and morphine self-administration in rats by the morphine-6beta-glucuronide antagonist 3-O-methylnaltrexone. , 1999, European journal of pharmacology.

[19]  P. Sánchez-Blázquez,et al.  Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[20]  I. Sora,et al.  The μ-opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in μ-opioid receptor knockout mice , 1999, Neuroscience.

[21]  G. Pasternak,et al.  Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. , 1999, Molecular pharmacology.

[22]  H. Ueda,et al.  Differential involvement of mu-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. , 1999, European journal of pharmacology.

[23]  A. Kastin,et al.  Differential distribution of endomorphin 1‐ and endomorphin 2‐like immunoreactivities in the CNS of the rodent , 1999 .

[24]  R. Przewłocki,et al.  Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. , 1999, European journal of pharmacology.

[25]  G. Pasternak,et al.  Retention of heroin and morphine–6β–glucuronide analgesia in a new line of mice lacking exon 1 of MOR–1 , 1999, Nature Neuroscience.

[26]  I. Sora,et al.  Absence of G‐protein activation by μ‐opioid receptor agonists in the spinal cord of μ‐opioid receptor knockout mice , 1999, British journal of pharmacology.

[27]  A. Kastin,et al.  Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers , 1998, Peptides.

[28]  G. Pasternak,et al.  Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. , 1998, The Journal of pharmacology and experimental therapeutics.

[29]  H. Akil,et al.  Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[30]  M. Narita,et al.  Characterization of endomorphin-1 and -2 on [35S]GTPgammaS binding in the mouse spinal cord. , 1998, European journal of pharmacology.

[31]  A. Kastin,et al.  Endomorphin 1 and 2 Have Vasodepressor Activity in the Anesthetized Mouse , 1998, Peptides.

[32]  S. Schulz,et al.  Immunofluorescent identification of endomorphin‐2‐containing nerve fibers and terminals in the rat brain and spinal cord , 1998, Neuroreport.

[33]  A. Cavalli,et al.  mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. , 1998, Brain research. Molecular brain research.

[34]  A. Herz Opioid reward mechanisms: a key role in drug abuse? , 1998, Canadian journal of physiology and pharmacology.

[35]  M. Wessendorf,et al.  Immunoreactivity for endomorphin‐2 occurs in primary afferents in rats and monkey , 1998, Neuroreport.

[36]  A. Kastin,et al.  Localization of Endomorphin-2-Like Immunoreactivity in the Rat Medulla and Spinal Cord , 1997, Peptides.

[37]  A. Kastin,et al.  Isolation of Relatively Large Amounts of Endomorphin-1 and Endomorphin-2 From Human Brain Cortex , 1997, Peptides.

[38]  L. Stone,et al.  Spinal analgesic actions of the new endogenous opioid peptides endomorphin‐1 and ‐2 , 1997, Neuroreport.

[39]  J. Li,et al.  Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. , 1997, The Journal of pharmacology and experimental therapeutics.

[40]  L. Leventhal,et al.  3‐Methoxynaltrexone, a selective heroin/morphine‐6β‐glucuronide antagonist , 1997, FEBS letters.

[41]  A. Kastin,et al.  A potent and selective endogenous agonist for the µ-opiate receptor , 1997, Nature.

[42]  D. Selley,et al.  Acute and Chronic Effects of Opioids on δ and μ Receptor Activation of G Proteins in NG108‐15 and SK‐N‐SH Cell Membranes , 1997 .

[43]  L. Tseng,et al.  Inhibition of spinal nitric oxide synthase by N ω -nitro-l-arginine blocks the release of met-enkephalin and antinociception induced by supraspinally administered β-endorphin in the rat , 1997, Neuroscience.

[44]  I. Sora,et al.  Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E. Nestler,et al.  Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment , 1997, Brain Research.

[46]  Brigitte L. Kieffer,et al.  Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.

[47]  F. Oehme Goodman and Gilman 's: The pharmacological basis of therapeutics , 1996 .

[48]  D. Selley,et al.  Effects of chronic morphine administration on mu opioid receptor- stimulated [35S]GTPgammaS autoradiography in rat brain , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[49]  G. Pasternak,et al.  Antisense mapping the MOR‐1 opioid receptor: evidence for alternative splicing and a novel morphine‐6β‐glucuronide receptor , 1995, FEBS letters.

[50]  J. Traynor,et al.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. , 1995, Molecular pharmacology.

[51]  M. Misawa,et al.  Blockade of morphine reward through the activation of κ-opioid receptors in mice , 1993, Neuropharmacology.

[52]  L. Tseng,et al.  Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse. , 1993, The Journal of pharmacology and experimental therapeutics.

[53]  Lei Yu,et al.  Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.

[54]  L. Tseng,et al.  Different mechanisms mediating tail-flick inhibition induced by beta-endorphin, DAMGO and morphine from ROb and GiA in anesthetized rats. , 1991, The Journal of pharmacology and experimental therapeutics.

[55]  L. Tseng,et al.  Different mechanisms mediate beta-endorphin- and morphine-induced inhibition of the tail-flick response in rats. , 1990, The Journal of pharmacology and experimental therapeutics.

[56]  G. Pasternak,et al.  Naloxonazine actions in vivo. , 1986, European journal of pharmacology.

[57]  G. Pasternak,et al.  Minireview: Multiple MU opiate receptors , 1986 .

[58]  M. Morgan,et al.  Analgesic, locomotor and lethal effects of morphine in the mouse: Strain comparisons , 1985, Brain Research.

[59]  R. Goodman,et al.  Autoradiographic distribution of Mu1 and Mu2 opioid binding in the mouse central nervous system , 1985, Brain Research.

[60]  R. Goodman,et al.  Autoradiographic analysis of mu1, mu2, and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid receptor-deficient) mice , 1985, Brain Research.

[61]  G. Pasternak,et al.  Visualization of mu1 opiate receptors in rat brain by using a computerized autoradiographic subtraction technique. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[62]  G. Pasternak,et al.  Classification of multiple morphine and enkephalin binding sites in the central nervous system. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[63]  C. Schuster,et al.  An analysis of drug-seeking behavior in animals , 1981, Neuroscience & Biobehavioral Reviews.

[64]  S. Snyder,et al.  Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. , 1981, Science.

[65]  L. Hood,et al.  Dynorphin-(1-13), an extraordinarily potent opioid peptide. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Choh Hao Li,et al.  β-Endorphin as a potent analgesic by intravenous injection , 1976, Nature.

[67]  H. Morris,et al.  Identification of two related pentapeptides from the brain with potent opiate agonist activity , 1975, Nature.

[68]  T. Shippenberg,et al.  Evidence that the aversive effects of opioid antagonists and κ-agonists are centrally mediated , 2004, Psychopharmacology.

[69]  M. Narita,et al.  Evidence for the Existence of the β-Endorphin-Sensitive “ε-Opioid Receptor” in the Brain: The Mechanisms of ε-Mediated Antinociception , 1998 .

[70]  D. Selley,et al.  mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. , 1997, Molecular pharmacology.

[71]  T. Reisine Opioid analgesics and antagonists , 1996 .

[72]  L. Recht,et al.  Biochemical characterization of high-affinity 3H-opioid binding. Further evidence for Mu1 sites. , 1984, Molecular pharmacology.